Skip to main content

Table 1 Subject Demographics and Baseline Characteristics

From: Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma

Demographic or Characteristic MF/F-MDI
200/10 μg BID (n = 371)
FP/S-DPI
250/50 μg BID (n = 351)
Sex, n (%)   
   Female 239 (64) 220 (63)
Race, n (%)   
   White 323 (87) 301 (86)
Mean age, y (range) 44.8 (12-82) 45.1 (12-80)
Duration of asthma, y   
   Mean 15.0 15.9
   Median 11.0 13.0
Prior ICS use, n (%)* 225 (61) 188 (54)
Prior ICS/LABA use, n (%)*   
   Budesonide/formoterol 59 (16) 59 (17)
   Fluticasone/salmeterol 104 (28) 115 (33)
Mean FEV1 at baseline   
   L 2.30 2.37
   Percentage predicted 73.8 74.4
Mean total ACQ score 1.80 1.80
Mean total AQLQ(S) score 5.14 5.14
  1. ACQ = Asthma Control Questionnaire; AQLQ(S) = Asthma Quality of Life Questionnaire With Standardized Activities; BID = twice daily; DPI = dry powder inhaler; FEV1 = forced expiratory volume in 1 s; FP/S = fluticasone propionate/salmeterol; ICS = inhaled corticosteroid; LABA = long-acting β2-agonist; MDI = metered-dose inhaler; MF/F = mometasone furoate/formoterol.
  2. *Subjects could have received multiple types of ICS monotherapy and combination ICS/LABA therapy in the 3 months before screening.
  3. ACQ score based on a 7-point scale that ranged from 0 (best asthma control) to 6 (worst asthma control).
  4. AQLQ(S) score based on a 7-point scale that ranged from 1 (worst quality of life) to 7 (best quality of life)